ArticleJournal of cancer research and clinical oncology2023

AHR, a novel inhibitory immune checkpoint receptor, is a potential therapeutic target for chemoresistant glioblastoma.

Nian Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.